中国处方药
中國處方藥
중국처방약
CHINA PRESCRIPTION DRUG
2014年
12期
12-13
,共2页
磷结合剂%维持性血液透析%高磷血症%对比研究
燐結閤劑%維持性血液透析%高燐血癥%對比研究
린결합제%유지성혈액투석%고린혈증%대비연구
Phosphate binder%Hemodialysis%Hyperphosphatemia%Comparative study
目的:观察对比2种不同的磷结合剂对维持性血液透析患者高磷血症的治疗效果。方法选取肾内科维持性血液透析并高磷血症患者64例,随机分为观察组和对照组各32例,对照组应用碳酸钙治疗,观察组应用盐酸司维拉姆进行治疗。观察两组患者的治疗有效率及血液生化指标中血清高密度脂蛋白、血磷、血清钙磷乘积的变化情况及不良反应。结果治疗后,观察组和对照组患者血磷、血清钙磷的乘积均较治疗前显著下降,差异具有统计学意义(P<0.05);观察组这两项指标下降更为明显,与对照组相比差异具有统计学意义(P<0.05);观察组的治疗有效率显著高于对照组(P<0.05);观察组患者血清高密度脂蛋白较治疗前显著上升(P<0.05);观察组高钙血症发生率低于对照组,但差异无统计学意义(P>0.05)。结论盐酸司维拉姆比碳酸钙对维持性血液透析患者高磷血症具有更好的短期疗效。
目的:觀察對比2種不同的燐結閤劑對維持性血液透析患者高燐血癥的治療效果。方法選取腎內科維持性血液透析併高燐血癥患者64例,隨機分為觀察組和對照組各32例,對照組應用碳痠鈣治療,觀察組應用鹽痠司維拉姆進行治療。觀察兩組患者的治療有效率及血液生化指標中血清高密度脂蛋白、血燐、血清鈣燐乘積的變化情況及不良反應。結果治療後,觀察組和對照組患者血燐、血清鈣燐的乘積均較治療前顯著下降,差異具有統計學意義(P<0.05);觀察組這兩項指標下降更為明顯,與對照組相比差異具有統計學意義(P<0.05);觀察組的治療有效率顯著高于對照組(P<0.05);觀察組患者血清高密度脂蛋白較治療前顯著上升(P<0.05);觀察組高鈣血癥髮生率低于對照組,但差異無統計學意義(P>0.05)。結論鹽痠司維拉姆比碳痠鈣對維持性血液透析患者高燐血癥具有更好的短期療效。
목적:관찰대비2충불동적린결합제대유지성혈액투석환자고린혈증적치료효과。방법선취신내과유지성혈액투석병고린혈증환자64례,수궤분위관찰조화대조조각32례,대조조응용탄산개치료,관찰조응용염산사유랍모진행치료。관찰량조환자적치료유효솔급혈액생화지표중혈청고밀도지단백、혈린、혈청개린승적적변화정황급불량반응。결과치료후,관찰조화대조조환자혈린、혈청개린적승적균교치료전현저하강,차이구유통계학의의(P<0.05);관찰조저량항지표하강경위명현,여대조조상비차이구유통계학의의(P<0.05);관찰조적치료유효솔현저고우대조조(P<0.05);관찰조환자혈청고밀도지단백교치료전현저상승(P<0.05);관찰조고개혈증발생솔저우대조조,단차이무통계학의의(P>0.05)。결론염산사유랍모비탄산개대유지성혈액투석환자고린혈증구유경호적단기료효。
Objective To observe and campare the clinical effect of 2 kinds of phosphate binder in the treatment of maintenance hemodialysis patients with hyperphosphatemia.Methods 64 maintenance hemodialysis patients with hyperphosphatemia were collected and randomly divided into two groups, 32 cases of each group . patients in the control group received calcium carbonate for hyperphosphatemia treatment, and the patients in observation group received Hydrochloride Division Wei Lamu hyperphosphataemia treatment. Then to observe changes of the treatment efficiency, blood biochemical parameters in serum high-density lipoprotein, phosphorus, serum calcium phosphorus product and adverse reactions.Results After treatment, patients’ phosphorus, serum calcium and phosphorus product were significantly decreased than before treatment(P<0.05), and these two indicators of the observation group were significantly decreased more than those of the conctrol group(P<0.05); observation group treatment efficiency were significantly higher(P<0.05); blood biochemical parameters in serum high-density lipoprotein of the observation group was significant higher than that of the conctrol group(P<0.05);The incidence of hypercalcemia in the observation group was less than that in the control group, but the difference had no statistically significant(P>0.05). Conclusion Sevelamer hydrochloride in maintenance hemodialysis patients with hyperphosphatemia has better short-term results than calcium carbonate.